BIROn - Birkbeck Institutional Research Online

    New approaches to the use of Selegine for the treatment of Parkinson's disease

    Lees, A.J. and Frankel, J. and Eatough, Virginia and Stern, G. (1989) New approaches to the use of Selegine for the treatment of Parkinson's disease. Acta Neurologica Scandinavica 80 (s126), pp. 139-145. ISSN 1600-0404.

    Full text not available from this repository.


    Selegiline hydrochloride (deprenyl) is a safe, useful adjuvant therapy in patients with Parkinson's disease treated with L‐dopa. The optimum time for its introduction into the treatment regimen of a patient remains controversial. A multi‐centre long‐term study being conducted by the Parkinson's Disease Research Group of the United Kingdom to attempt to answer whether selegiline improves the natural history of Parkinson's disease is discussed. In a separate study we have been unable to demonstrate that higher doses of selegiline (up to 40 mg a day) produce additional therapeutic benefit above the conventional dose of 10 mg a day in levodopa‐treated patients with motor fluctuations. Preliminary data from a neuropsychological study is also presented which suggests that selegiline may have beneficial effects on the speed of psychomotor responses supporting the anecdotal clinical observations of increased mental energy and alacrity.


    Item Type: Article
    School: Birkbeck Faculties and Schools > Faculty of Science > School of Psychological Sciences
    Depositing User: Sarah Hall
    Date Deposited: 25 Nov 2019 16:05
    Last Modified: 02 Aug 2023 17:55


    Activity Overview
    6 month trend
    6 month trend

    Additional statistics are available via IRStats2.

    Archive Staff Only (login required)

    Edit/View Item Edit/View Item